Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00326326 | Effect of CP-778,875 on HDL-C in Subjects With Abnormal Lipid Levels and Type 2 Diabetes. | PHASE2 | COMPLETED | 84 | — | — | Jul 1, 2006 | Jun 1, 2007 | May 7, 2009 | 31 | United States |
| Name | Type | Description |
|---|---|---|
| CP-778,875 | DRUG | - |
Inclusion Criteria: * HDL-C \< or = 45 mg/dL for men and \< or = 55 mg/dL for women * Triglycerides between 150-500 mg/dL * Fasting Plasma Glucose 140-240 mg/dL Exclusion Criteria: * Known cardiovascular, carotid, or peripheral vascular disease